TW202208430A - SIRPα、SIRPβ1及SIRPγ抗體及其用途 - Google Patents

SIRPα、SIRPβ1及SIRPγ抗體及其用途 Download PDF

Info

Publication number
TW202208430A
TW202208430A TW110116827A TW110116827A TW202208430A TW 202208430 A TW202208430 A TW 202208430A TW 110116827 A TW110116827 A TW 110116827A TW 110116827 A TW110116827 A TW 110116827A TW 202208430 A TW202208430 A TW 202208430A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
acid sequence
nucleic acid
chain variable
Prior art date
Application number
TW110116827A
Other languages
English (en)
Chinese (zh)
Inventor
珊迪普 潘尼克
亞當 大衛 羅森塔爾
伊琳 靈休 羅斯
Original Assignee
美商電子療法股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商電子療法股份有限公司 filed Critical 美商電子療法股份有限公司
Publication of TW202208430A publication Critical patent/TW202208430A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
TW110116827A 2020-05-08 2021-05-10 SIRPα、SIRPβ1及SIRPγ抗體及其用途 TW202208430A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08

Publications (1)

Publication Number Publication Date
TW202208430A true TW202208430A (zh) 2022-03-01

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110116827A TW202208430A (zh) 2020-05-08 2021-05-10 SIRPα、SIRPβ1及SIRPγ抗體及其用途
TW110116828A TW202208431A (zh) 2020-05-08 2021-05-10 SIRPα及SIRPβ1抗體及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110116828A TW202208431A (zh) 2020-05-08 2021-05-10 SIRPα及SIRPβ1抗體及其用途

Country Status (11)

Country Link
US (4) US12503508B2 (cg-RX-API-DMAC7.html)
EP (2) EP4146699A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525298A (cg-RX-API-DMAC7.html)
KR (2) KR20230017793A (cg-RX-API-DMAC7.html)
CN (2) CN115768795A (cg-RX-API-DMAC7.html)
AU (2) AU2021269130A1 (cg-RX-API-DMAC7.html)
CA (2) CA3178038A1 (cg-RX-API-DMAC7.html)
GB (2) GB2613259A (cg-RX-API-DMAC7.html)
IL (2) IL297982A (cg-RX-API-DMAC7.html)
TW (2) TW202208430A (cg-RX-API-DMAC7.html)
WO (2) WO2021226591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
TW202330911A (zh) * 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性t細胞及其製作方法
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202547858A (zh) 2024-04-22 2025-12-16 美商電子療法股份有限公司 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) * 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
CN111511766B (zh) * 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
CR20200566A (es) * 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
MX2021015937A (es) 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.
EP4110819A1 (en) 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
EP4429768A2 (en) 2021-11-10 2024-09-18 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之sirp抗體

Also Published As

Publication number Publication date
US20230174648A1 (en) 2023-06-08
GB2613259A (en) 2023-05-31
JP2023525753A (ja) 2023-06-19
US20250197492A1 (en) 2025-06-19
US20230303685A1 (en) 2023-09-28
GB2613464A (en) 2023-06-07
KR20230017219A (ko) 2023-02-03
US12503508B2 (en) 2025-12-23
JP2023525298A (ja) 2023-06-15
EP4146698A1 (en) 2023-03-15
US12187797B2 (en) 2025-01-07
CN115768796A (zh) 2023-03-07
GB202218419D0 (en) 2023-01-18
AU2021267943A1 (en) 2022-11-24
CA3178038A1 (en) 2021-11-11
CN115768795A (zh) 2023-03-07
IL297982A (en) 2023-01-01
WO2021226591A1 (en) 2021-11-11
JP7894204B2 (ja) 2026-07-23
IL298024A (en) 2023-01-01
KR20230017793A (ko) 2023-02-06
CA3177961A1 (en) 2021-11-11
US20240239888A1 (en) 2024-07-18
GB202218421D0 (en) 2023-01-18
EP4146699A1 (en) 2023-03-15
TW202208431A (zh) 2022-03-01
AU2021269130A1 (en) 2022-11-24
WO2021226576A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JP7584588B2 (ja) 抗sirpa抗体およびその使用法
US11254743B2 (en) Anti-CD33 antibodies and methods of use thereof
US12187797B2 (en) SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof
US20260022175A1 (en) Anti-ctla-4 antibody and use thereof
CN120757649A (zh) 抗-ctla-4抗体及其用途
KR20210030341A (ko) 항-Siglec-7 항체 및 그의 사용 방법
TW202229340A (zh) 多特異性抗體及抗體組合
TW202304984A (zh) 抗人類cxcr5抗體及其用途
CA3220353C (en) Use of anti-ctla-4 antibody
HK40099253A (en) Use of anti-ctla-4 antibody
HK40099253B (en) Use of anti-ctla-4 antibody
EA049679B1 (ru) Анти-sirpa антитела и способы их применения
EA044628B1 (ru) Анти-sirpa антитела и способы их применения
HK40042330B (en) Anti-sirpa antibodies and methods of use thereof
HK40016537B (en) Anti-pd-1 antibodies and uses thereof